YD Bio Limited Expands OkaiDx^™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the US and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited provided an update regarding US access to the OkaiDx^™ platform for post‑treatment breast cancer monitoring, detailing the continued expansion of OkaiDx^™ blood‑based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection.